Saturday, 31 October 2026European Markets

MCPHY ENERGY Stock Bullish Momentum With A 15.1% Jump Before The Weekend

Loading stream...

(vianews) - the market ended the session with mcphy energy (mcphy.pa) jumping 15.1% to €4.68 on friday, after two sequential sessions in a row of gains. cac 40 fell 0.19% to €7,047.50, after four consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

mcphy energy's last close was €4.07, 72.71% under its 52-week high of €14.90.

about mcphy energy

mcphy energy s.a. provides hydrogen production and distribution equipment for hydrogen energy, hydrogen mobility, and industrial hydrogen markets. the company offers alkaline electrolyzers; hydrogen storage and transportation solutions; and fuel cell systems. it also develops hydrogen stations; and provides integrated hydrogen solutions. the company operates in europe, the middle east, africa, the americas, and the asia pacific. mcphy energy s.a. was incorporated in 2007 and is headquartered in grenoble, france.

earnings per share

as for profitability, mcphy energy has a trailing twelve months eps of €-1.51.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -31.8%.

volatility

mcphy energy's last week, last month's, and last quarter's current intraday variation average was a positive 3.61%, a negative 0.90%, and a positive 2.51%.

mcphy energy's highest amplitude of average volatility was 6.94% (last week), 3.07% (last month), and 2.51% (last quarter).

moving average

mcphy energy's value is way below its 50-day moving average of €5.33 and way under its 200-day moving average of €9.47.

volume

today's last reported volume for mcphy energy is 220215 which is 190.29% above its average volume of 75858.

more news about mcphy energy (mcphy.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com